| Trial name or title | Ascorbic Acid Treatment in CMT1A Trial (AATIC) |
| Methods | |
| Participants | CMT1A patients genetically carrying the duplication on chromosome 17q11.2 between 12‐25 years |
| Interventions | Ascorbic acid for 1 year. |
| Outcomes | Change in motor nerve conduction velocity of the median nerve after 1 year primary outcome, Secondary Outcome Measures: * Change in minimal F response latency of the median nerve after 1 year. * Changes in compound muscle action potential amplitude and area after 1 year. * Change in motor unit number estimation of the abductor pollicis brevis muscle after 1 year. * Changes in handgrip strength, strength of armflexors, foot dorsiflexors, knee extensors and hip flexors after 1 year. * Change in overall disability sum score after 1 year. * Change in AMC Linear Disability Scale score after 1 year. * Evaluation of serum ascorbic acid concentrations during 1 year. * Evaluation of side effects during 1 year. |
| Starting date | January 2006 |
| Contact information | Department of Neurology Academic Medical Center University of Amsterdam, Amsterdam, P.O.Box 22660, 1100 DD, Netherlands; Recruiting C. Verhamme, MD +31‐20‐5663856 c.verhamme@amc.uva.nl |
| Notes | Listed at ClinicalTrials.gov |
Ascorbic acid in CMT1A trial (AATIC) Maximum voluntary isometric contraction (MVIC) Academic medical center Linear Disability Scale (AMC Linear Disability Scale) Visual analog scale (VAS) Overall neuropathy limitations scale (ONLS)